# Multiple Dose Pharmacokinetics of Canagliflozin/Metformin 150/1,000 mg Fixed Dose Combination

> **NCT02039245** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 12 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** CANA/MET XR FDC

## Key facts

- **NCT ID:** NCT02039245
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2014-02
- **Final completion:** 2014-03
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2014-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02039245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02039245, "Multiple Dose Pharmacokinetics of Canagliflozin/Metformin 150/1,000 mg Fixed Dose Combination". Retrieved via AI Analytics 2026-06-21 from https://api.ai-analytics.org/clinical/NCT02039245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*